LONDON (Alliance News) - ANGLE PLC said Thursday that Barts Cancer Institute has published its work in prostate cancer patients using ANGLE's Parsortix system in the PLOS ONE Journal.
The work showed that using the Parsortix system researchers were able to successfully harvest cancer cells from 100% of the patients for analysis. The Parsortix system can capture specific cells from blood, allowing for a blood test to be used as a non-invasive liquid biopsy for cancer patients.
"This is the first peer-reviewed publication in a scientific journal in relation to the clinical use of ANGLE's Parsortix system. It adds to the growing body of published evidence of the system's performance as a liquid biopsy in a range of cancers including ovarian, prostate and breast cancers. The prospect of deployment of our repeatable, non-invasive liquid biopsy in the treatment of prostate cancer patients is exciting," said Chief Executive and Founder Andrew Newland in a statement.
Shares in ANGLE were up 6.6% at 81.00 pence Thursday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Angle (AGL)